Cellivery Obtains Patent Rights in Europe for Candidate Substances Treating Severe Obesity and Diabetes
[Asia Economy Reporter Minji Lee] Cellivery announced on the 17th that it has obtained a patent for a candidate substance for the treatment of severe obesity and diabetes with leptin resistance.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The patent registration country is the European Union. The company explained, "We can negotiate from a favorable position during technology transfer discussions with global pharmaceutical companies."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
